The Europe Cell Therapy Market would witness market growth of 25.3% CAGR during the forecast period (2020-2026). The arrival of modern technologies has encouraged the development of advanced cellular therapies growth.
Companies are using the latest technologies with an aim to increase their product offerings and set-up out-licensing or co-development agreements with other bodies to encourage their product development programs.
Cell-based therapies have the power for substituting, repairing, restoring, or regenerating damaged tissues, and organs. Researchers are putting huge investments in the development of these effective and secure treatments as an option to traditional treatment strategies which can be further supporting the market growth. Among all therapeutic segments, oncology has the biggest number of ongoing clinical trials. For the clinical investigation, mesenchymal stem/stromal cells, CD34+ and/or CD133+ cells, and T cells are used.
The surge in occurrences of the population suffering from cardiovascular, cancer, and other diseases are anticipated to boost the growth of the market. In addition, increasing initiatives undertook by authorities and governments to enhance healthcare systems and spread awareness about the advantages of cell therapy are also anticipated to push the development of the market growth.
The increasing number of clinical studies for cell-based therapies is boosting the growth of the market. This has brought considerable global funding in R&D and their clinical translation. The rising number of ongoing clinical trials is the result of the existence of government and private funding agencies that are consistently providing investments to promote projects across several phases of clinical trials.
The Germany market dominated the Europe Musculoskeletal Disorders Market by Country 2019, growing at a CAGR of 24.9 % during the forecast period. The UK market is exhibiting a CAGR of 25.3% during (2020 - 2026). Additionally, The France market is anticipated to witness a CAGR of 27.1% during (2020 - 2026).
The Academic & Research Institutes market dominated the Russia Cell Therapy Market by End User 2019, thereby, achieving a market value of $682.5 million by 2026. The Hospitals & Clinics market is expected to witness highest CAGR of 26.5% during (2020 - 2026).
Based on Therapy Type, the market is segmented into Autologous and Allogeneic. Based on Therapeutic Area, the market is segmented into Malignancies, Autoimmune Disorders, Musculoskeletal Disorders, Dermatology and Others. Based on End User, the market is segmented into Academic & Research Institutes and Hospitals & Clinics. Based on Cell Type, the market is segmented into Stem Cell, Umbilical Cord-Derived, Adipose-Derived Stem Cell, Non-Stem Cell, Bone Marrow, Blood and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: Cell Therapy Market in Europe is expected to register a CAGR of 25.3% during the forecast period (2020-2026)
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Fujifilm Holdings Corporation, Smith & Nephew PLC, Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., Medipost Co., Ltd., Stemedica Cell Technologies, Inc., NuVasive, Inc., Avantor, Inc., Vericel Corporation, and Pharmicell Co., Ltd.
By Therapy Type
By Therapeutic Area
By End User
By Cell Type
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
